dr zafar semaglutide Dr. Shahzad Zafar, MD, Stamford, CT FDA Approves Oral Semaglutide as

By March 2024, the FDA approved Semaglutide injection (Wegovy) as the first drug to reduce the risk of serious heart disease in obese or overweight adults

Tumor cell-intrinsic epigenetic dysregulation shapes cancer-associated fibroblasts heterogeneity to metabolically support pancreatic cancer

Significant Weight Loss: When used alongside diet and exercise, semaglutide and tirzepatide have been shown to result in substantial weight loss, making them a powerful tool in managing obesity and related health conditions

[DOI] [PMC free article] [PubMed] [Google Scholar] 35.Nagashima R., Kosai H., Masuo M., Izumiyama K., Noshikawaji T., Morimoto M., Kumaki S., Miyazaki Y., Motohashi H., Yamamoto M., et al